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Treating hemodialysis patients to combat anemia corrects
hemoglobin but exacerbates iron deficiency by utilizing iron
stores. Patients needing iron should receive this by
intravenous (i.v.) means. The Dialysis patients’ Response to
IV iron with Elevated ferritin (DRIVE) trial investigated the role
of i.v. iron in anemic patients with high ferritin, low
transferrin saturation, and adequate epoetin doses. We
examined whether baseline iron and inflammation markers
predict the response of hemoglobin to treatment. Patients
(134) were randomized to no added iron or to i.v. ferric
gluconate for eight consecutive hemodialysis sessions
spanning 6 weeks with epoetin increased by 25% in both
groups. The patients started with hemoglobin less than or
equal to 11 g/dl, ferritin between 500 and 1200 ng/ml, and
transferrin saturation of less than 25%. Significantly, patients
with a reticulocyte hemoglobin content greater than or equal
to 31.2 pg were over five times more likely to achieve a
clinically significant increase in hemoglobin of greater than
2 g/dl. Lower reticulocyte hemoglobin contents did not
preclude a response to i.v. iron. Significantly higher
transferrin saturation or lower C-reactive protein but not
ferritin or soluble transferrin receptor levels predicted a
greater response; however their influence was not clinically
significant in either group. We conclude that none of the
studied markers is a good predictor of response to anemia
treatment in this patient sub-population.
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Anemia treatment in the hemodialysis population with
erythropoiesis-stimulating agents increases hemoglobin but
consumes iron stores, frequently resulting in iron deficiency.
Blood loss in the dialysis circuit, laboratory testing,
interventional procedures, and gastrointestinal bleeding lead
to continuing iron losses.1 Oral iron therapy is usually
ineffective in providing sufficient iron in this population.1,2
Consequently, the National Kidney Foundation-Kidney
Disease Outcome Initiative (NKF-KDOQI) strongly recom-
mends that hemodialysis patients needing iron should be
treated with intravenous (i.v.) iron therapy.1–3
Serum ferritin and transferrin saturation (TSAT) are
routinely utilized in dialysis patients to aid in diagnosing iron
deficiency and in guiding iron therapy. Uniformly low TSAT
(o20%) and ferritin (o200ng/ml) are clear indicators of
iron deficiency and predict a higher likelihood of response to
i.v. iron.1 When TSAT and ferritin are both elevated, that is,
TSAT 420% and ferritin 4200 ng/ml, adequate iron stores
are likely present and the likelihood of response to iron is
low. However, ferritin and TSAT values are frequently
discordant, as they are, respectively, positive and negative
acute phase reactants.4 Consequently, in the setting of
inflammation or malnutrition, simultaneously high ferritin
and low TSAT are frequently encountered and difficult to
evaluate.1,2
Ideally, other tests could predict responsiveness to i.v.
iron. Studies in hemodialysis patients have repeatedly found
TSAT and ferritin as poor predictors of hemoglobin
responsiveness to i.v. iron.5–9 However, these studies have
several limitations, including enrolling limited numbers of
patients with ferritin values 4500 ng/ml and lack of adequate
control groups.4 The 2006 KDOQI Anemia guidelines noted
a lack of sufficient evidence of responsiveness to iron when
ferritin is 4500 ng/ml, and stated ‘routine administration’
could not be recommended.1 Additionally, the guidelines
recommended use of reticulocyte hemoglobin content (CHr)
o29 pg/cell as an indicator of iron deficiency.1 When
evaluating iron needs in patients with ferritin 4500 ng/ml,
factors such as erythropoiesis-stimulating agents dose,
http://www.kidney-international.org o r i g i n a l a r t i c l e
& 2007 International Society of Nephrology
Received 15 December 2006; revised 31 January 2007; accepted 6
February 2007; published online 28 March 2007
Correspondence: AK Singh, Brigham and Women’s Hospital, 75 Francis
Street, Boston, MA 02115, USA. Email: asingh@partners.org
Kidney International (2007) 71, 1163–1171 1163
clinical status, TSAT values, and hemoglobin trends should
be taken into account.1
Since release of the 2006 KDOQI anemia guidelines, the
Dialysis Patients’ Response to i.v. iron with Elevated ferritin
(DRIVE) study has demonstrated that ferric gluconate was
superior to no iron in improving hemoglobin levels in
anemic hemodialysis patients with ferritin of 500–1200 ng/ml
and TSATp25%.10 By week 6, patients receiving 1 g of ferric
gluconate in addition to a 25% increase in epoetin dose
experienced a mean hemoglobin change of 1.6 g/dl compared
with only 1.1 g/dl in patients receiving a 25% increase in
epoetin dose alone. In addition, the ferric gluconate patients
mounted a clinically significant hemoglobin response more
frequently and more quickly than the no iron patients. The
amount of i.v. iron received by either patient group in the
4 weeks before enrollment had no impact on hemoglobin
change.10 Further, in the observational extension study of
DRIVE, also known as DRIVE-II, hemoglobin changes were
sustained until at least week 12 from the start of therapy
despite significantly lower epoetin doses in the patients
randomized to ferric gluconate (Kapoian et al. J Am Soc
Nephrol 2006; 17: 479A).
In this report we explore the value of ferritin, TSAT, CHr,
C-reactive protein (CRP), and soluble transferrin receptor
(sTfR) as predictors of iron responsiveness based on the
DRIVE study data, which were pre-specified objectives of that
trial. We also investigated the effect of increasing epoetin
doses on responsiveness, an important treatment component
that has not been studied previously.
RESULTS
Of the 134 randomized patients, 129 were included in the
intent-to-treat (ITT) population (no iron n¼ 65, i.v. iron
n¼ 64).10 Of those 129 patients, 93 were included in the per-
protocol (PP) population (no iron n¼ 50, i.v. iron n¼ 43).
Baseline demographic and laboratory characteristics were
similar in the two groups in both the ITT and PP populations
(Table 1). Of note, 480% of the patients had a baseline CHr
429 pg/cell, the target CHr level recommended by the 2006
KDOQI clinical practice recommendations.1 Changes in
homocysteine levels were similar in the two groups (median
change; i.v. iron 0.5mmol/L vs no iron 1.7mmol/L, P¼ 0.598).
We attempted to explore the underlying reason why
patients had a baseline ferritin at or above vs below the
Table 1 | Baseline characteristics by treatment group and analysis population
ITT population PP populationa
No iron i.v. iron No iron i.v. iron
Parameter (N=65) (N=64) (N=50) (N=43)
Age (years) 58.7715.2 61.2713.0 59.1714.9 60.3712.6
Females (n (%)) 37 (56.9) 27 (42.2) 29 (58.0) 21 (48.8)
Weight (kg) 75.0722.3 76.4721.0 77.6723.0 71.2713.8
Height (cm) 168.179.8 171.9736.1 168.979.9 165.179.6
Race, n (%)
White 20 (30.8) 20 (31.3) 17 (34.0) 13 (30.2)
African American 33 (50.8) 30 (46.9) 26 (52.0) 20 (46.5)
Hispanic 9 (13.8) 9 (14.1) 6 (12.0) 6 (14.0)
Asian/Pacific Islander 2 (3.1) 5 (7.8) 1 (2.0) 4 (9.3)
Other 1 (1.5) 0 (0.0) 0 (0.0) 0 (0.0)
Hemodialysis access, n (%)
AV fistula 30 (46.2) 33 (51.6) 26 (52.0) 20 (46.5)
AV graft 21 (32.3) 20 (31.3) 14 (28.0) 15 (34.9)
Temporary catheter 3 (4.6) 2 (3.1) 2 (4.0) 1 (2.3)
Permanent catheter 11 (16.9) 9 (14.1) 8 (16.0) 7 (16.3)
i.v. iron in previous 4 weeks, n (%) 24 (36.9) 22 (34.4) 21 (42.0) 13 (30.2)
i.v. iron given in previous 4 weeks (mg) 707108 617103 79.57113.4 41.9769.2
Homocysteine (mmol/l) 27.379.8 25.478.2 27.879.1 25.076.9
Most recent Kt/V 1.770.3 1.670.4 1.770.3 1.770.4
Hemoglobin (g/dl) 10.270.7 10.470.8 10.270.7 10.470.8
TSAT (%) 19.074.1 18.274.2 19.373.9 18.074.4
Serum ferritin (ng/ml) 7657193 7597190 7687182 7727200
CHr (pg/cell) 31.072.8 31.472.7 31.272.8 31.972.7
CHr429 pg/cell, n (%) 54 (83.1) 51 (79.7) 43 (86.0) 36 (83.7)
sTfr (mg/l) 6.172.2 6.272.5 5.972.3 6.372.6
C-reactive protein (mg/l)b 25.5729.3 29.3739.2 22.0723.1 25.5734.5
Epoetin dose (IU/kg/week) 4957272 4487229 4447234 4527227
CHr, reticulocyte hemoglobin content; ITT, intent-to-treat; PP, per-protocol; TSAT, transferrin saturation; sTfr, soluble transferrin receptor.
Continuous variables are summarized using mean7s.d.
aMore i.v. iron patients than no iron patients were excluded from the PP population because they had to satisfy one more criterion to be in the PP population (receiving the
entire 1 g of i.v. ferric gluconate).
bC-reactive protein values were obtained using the high-sensitivity assay.
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median (true iron stores or inflammation) by tabulating the
number of patients who had TSAT, CHr, CRP, or albumin at/
above vs. below the respective median and by dividing
patients according to the degree of response. We did not
observe any significant differences (data not shown).
The proportions of patients achieving hemoglobin
increases 41 g/dl in any 2-week period were 40.9 and
43.9% in the no iron and the i.v. iron groups, respectively
(P¼ 0.725). Regardless of treatment arm, those with baseline
CRPo14.1 mg/l were 3.3 times more likely to experience this
rate of increase (P¼ 0.001).
Hemoglobin change and baseline values of response markers
Table 2 summarizes the impact of one unit change in TSAT,
ferritin, CHr, sTfR, CRP, and epoetin dose increase (referred
to henceforth as response markers) on hemoglobin change
from baseline to week 6 while controlling for the i.v. iron
treatment effect and baseline hemoglobin values. Table 2 also
summarizes how i.v. iron impacted hemoglobin change when
adjusting for each of the studied response markers.
In the ITT population, while TSAT, CRP, and epoetin dose
increase influenced hemoglobin change regardless of treat-
ment (TSAT, P¼ 0.025; CRP, P¼ 0.006; epoetin dose,
P¼ 0.001), only epoetin dose increase resulted in a clinically
significant change in hemoglobin levels. For every 1%
increase in baseline TSAT, hemoglobin increased by only
0.06 g/dl (95% confidence interval (CI)¼ 0.01–0.12 g/dl). Every
1 mg/l increase in baseline CRP predicted a change of only
0.01 g/dl in hemoglobin at week 6 (95% CI¼0.02,
0.00 g/dl). In contrast, each 1 IU/kg/week increase in baseline
epoetin dose predicted an increase of 0.006 g/dl in hemoglobin
(95% CI¼ 0.001–0.010). Considering that the mean baseline
epoetin dose in the study was B500 IU/kg/week (Table 1) and
that the protocol mandated a 25% increase for all patients, the
resulting increase of 125 IU/kg/week effectively enhanced the
rise of hemoglobin from baseline byB0.8 g/dl, independent of
study treatment. The PP analysis confirmed the same findings
for CRP and epoetin dose increase only. Baseline serum ferritin,
CHr, and sTfR had no statistically significant effect on
hemoglobin change at week 6 in both the ITT and the PP
analyses.
In both analysis populations, administration of 1 g of
ferric gluconate to the i.v. iron group predicted greater
hemoglobin change at week 6 by 0.5–0.7 g/dl (Po0.05)
regardless of the baseline value of any of the response
markers including epoetin dose increase (Table 2). Baseline
homocysteine levels had no impact on hemoglobin change
(P40.4 in both analysis populations). In virtually all the
models, a 1 g/dl decrease in baseline hemoglobin values was
associated with 0.3–0.7 g/dl increase in hemoglobin at week 6
(Po0.05).
Hemoglobin increase X2 g/dl and baseline values of
response markers
Figure 1a–f and Figure 2a–f summarize the odds ratios (ORs)
of achieving a hemoglobin response (X2g/dl increase) if
patients had baseline values at/above vs. below the median of
each response marker in the no iron and i.v. iron groups,
respectively. Values below the median were the reference
category. Table 3 summarizes the sensitivity and specificity of
using median response markers’ baseline values in predicting
hemoglobin response X2g/dl.
Table 2 | Impact of one unit change in each response marker and use of i.v. iron on change in hemoglobina
Intent-to-treat population (N=129) Per-protocol population (N=93)
Response marker Model Parameter Coefficient (95% CI)b P-value Coefficient (95% CI)b P-value
TSAT Baseline TSAT 0.06 (0.01–0.12) 0.025 0.03 (0.04–0.09) 0.404
Receiving i.v. iron 0.59 (0.12–1.0) 0.013 0.69 (0.18–1.21) 0.009
Ferritin Baseline ferritin 0.000 (0.001–0.001) 0.721 0.000 (0.002–0.001) 0.712
Receiving i.v. iron 0.52 (0.06–0.99) 0.028 0.66 (0.15–1.17) 0.012
CHr Baseline CHr 0.07 (0.02–0.15) 0.131 0.08 (0.02–0.17) 0.101
Receiving i.v. iron 0.51 (0.05–0.98) 0.032 0.62 (0.11–1.13) 0.018
sTfR Baseline sTfR 0.07 (0.03–0.17) 0.175 0.08 (0.02–0.19) 0.110
Receiving i.v. iron 0.50 (0.04–0.97) 0.035 0.60 (0.09–1.11) 0.022
CRP Baseline CRP 0.01 (0.02–0.00) 0.006 0.01 (0.02–0.00) 0.008
Receiving i.v. iron 0.58 (0.12–1.0) 0.014 0.71 (0.22–1.20) 0.005
Epoetin Increase in dosea 0.006 (0.003–0.010)c 0.001 0.005 (0.000–0.009) 0.045
Receiving i.v. iron 0.5 (0.1–1.00) 0.017 0.6 (0.1–1.1) 0.018
95% CI, 95% confidence interval; TSAT, transferrin saturation; CHr, reticulocyte hemoglobin content; sTfR, soluble transferrin receptor; CRP, C-reactive protein.
This table presents results of separate multiple regression models, one for each examined response marker. Each model included baseline hemoglobin, value of the response
marker being examined, and treatment arm (i.v. iron; yes/no).
aExamples of one unit changes: TSAT, from 18 to 19%; ferritin, from 550 to 551; CHr from 30 to 31 pg/cell; sTfR, from 5 to 6 mg/L; CRP, from 15 to 16 mg/l; Epoetin, from 75 to
76 IU/kg/week.
bThe response marker coefficient is the magnitude of change in hemoglobin at week 6 that is associated with one unit change in the baseline value of the response marker.
I.v. iron coefficient is the difference between administration of i.v. iron in the form of ferric gluconate and administration of no iron.
cMagnitude of increase in epoetin dose is in IU/kg/week, which is approximately 25% greater than the baseline dose given before the study started.
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Predictors of response in the no iron group
Within the no iron group (25% epoetin dose increase alone),
none of the response markers other than absolute value of
epoetin dose increase predicted a statistically and clinically
significant response to treatment. Despite all patients having
received a 25% increase in their baseline epoetin dose,
patients receivingX101 IU/kg/week increase in their baseline
epoetin dose were B7.03 times (95% CI¼ 2.00–24.76) more
likely to achieve a hemoglobin response X2 g/dl than those
receiving less (Figure 1f). A similar trend was noted in the PP
population. However, using a X101 IU/kg/week epoetin
increase as a predictor of response lacked adequate sensitivity
(48.4%) despite good specificity (88.2%; Table 3).
Predictors of response in the i.v. iron group
In the i.v. iron group, a higher baseline CHr (Figure 2c) and a
lower baseline CRP (Figure 2e) predicted greater likelihood
of response (Table 2). In the ITT population, the OR of
achieving X2 g/dl hemoglobin response in patients with
baseline CHrX31.2 pg/cell relative to those with lower values
was 5.3 (95% CI¼ 1.78–15.83). As noted in Table 3, using a
CHr level cutoff of X31.2 pg/cell to predict hemoglobin
response had acceptable specificity (75.0%), but mediocre
sensitivity (63.9%). This trend was also observed in the PP
analysis.
In the ITT analysis, CRPX14.1 mg/l was associated with a
significantly lower likelihood of response (OR 0.36, 95%
CI¼ 0.13–0.99). Only a trend was observed in the PP analysis.
We performed a multivariate logistic regression analysis
comparing i.v. iron with no iron while controlling for CRP
category. Regardless of baseline CRP category, patients
receiving i.v. iron were more likely to achieve a hemoglobin
response X2 g/dl than no iron patients (OR 2.18, 95%
CI¼ 1.04–4.57). Sensitivity and specificity of using a cutoff
value p14.0 mg/l did not predict response (Table 3).
DISCUSSION
The DRIVE study assessed the efficacy of i.v. iron in dialysis
patients with elevated ferritin and low TSAT receiving epoetin
doses X22 500 IU/week.10 In this report we explored the
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Figure 1 | Likelihood of response to anemia treatment without i.v. iron. (a–f) Ability of (a) transferrin saturation, (b) serum ferritin,
(c) reticulocyte hemoglobin content, (d) soluble transferrin receptor, (e) C-reactive protein, and (f) magnitude of epoetin dose increase to
predict likelihood of a clinically significant hemoglobin response (X2 g/dl increase in hemoglobin) to anemia treatment without the use of iron.
(f) Response appears to be primarily driven by the magnitude of epoetin dose increase (Po0.05).
1166 Kidney International (2007) 71, 1163–1171
o r i g i n a l a r t i c l e AK Singh et al.: Predicting response to anemia treatment
value of several parameters of iron status and inflammation
in predicting response to i.v. iron. We observed that in
patients being treated with i.v. iron, baseline CHrX31.2 pg/
cell strongly predicted the likelihood of achieving a clinically
important hemoglobin response compared with lower levels.
Higher CRP levels decreased the extent and likelihood of
mounting a response to i.v. iron, but did not exclude it.
Furthermore, we found that TSAT, ferritin, sTfR, and
increasing epoetin doses are poor predictors of response to
i.v. iron.
Unlike i.v. iron-treated patients, clinically significant
hemoglobin response in patients not receiving iron is
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Figure 2 | Likelihood of response to anemia treatment using i.v. iron. (a–f) Ability of (a) transferrin saturation, (b) serum ferritin,
(c) reticulocyte hemoglobin content, (d) soluble transferrin receptor, (e) C-reactive protein, and (f) magnitude of epoetin dose increase to
predict likelihood of a clinically significant hemoglobin response (X2 g/dl increase in hemoglobin) to 1 g of i.v. iron (8 125 mg ferric
gluconate). (c) Reticulocyte hemoglobin contentX31.2 pg/cell and (e) C-reactive proteino14.1 mg/l were associated with greater likelihood of
response to i.v. iron (both Po0.05). However, the likelihood of response to anemia treatment with i.v. iron was always greater than without i.v.
iron, regardless of any level of reticulocyte hemoglobin content, C-reactive protein, or any other analyte.
Table 3 | Discriminative properties of response to assigned treatment based on the intent-to-treat analysis
No iron i.v. iron
Response marker and value Sensitivity (%) Specificity (%) Sensitivity (%) Specificity (%)
Baseline TSATX19% 28.6 70.0 48.5 54.8
Baseline ferritinX726 ng/ml 27.3 68.8 46.9 53.1
Baseline CHrX31.2 pg/cell 26.7 68.6 63.9 75.0
Baseline sTfrX5.9 mg/l 35.3 77.4 42.4 48.4
Baseline CRPp14.0 mg/l 34.4 75.8 59.4 65.6
Increase in epoetin doseX101 IU/kg/week 48.4 88.2 48.5 54.8
CHr, reticulocyte hemoglobin content; sTfR, soluble transferrin receptor; TSAT, transferrin saturation.
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influenced almost exclusively by the absolute magnitude of
epoetin dose increase. Although all patients received the 25%
increase in epoetin dose recommended by the KDOQI
guidelines,1–3 those receivingX101 IU/kg/week increase were
much more likely to mount a clinically significant hemoglo-
bin response. This emphasizes the fact that the 25% epoetin
dose increase recommended by the KDOQI guidelines,
although reasonable, appears inadequate for the treatment
of all patients with ferritin of 500–1200 ng/ml, TSAT p25%,
and baseline epoetin dosesX225 IU/kg/week orX22 500 IU/
week. Although C-reactive protein has a statistically sig-
nificant impact on hemoglobin change, the impact does not
appear to be clinically meaningful (Figure 1e). Regardless of
baseline values of TSAT, ferritin, CHr, sTfR, or CRP or
magnitude of epoetin dose increase, i.v. ferric gluconate given
to the i.v. iron group consistently results in a greater
hemoglobin response than giving no iron.
We chose a 2 g/dl increase in hemoglobin as a clinically
significant response because all patients received a 25%
increase in epoetin dose at the start and were expected to
experienceX1 g/dl increase during the study. Thus, a stricter
definition of response was warranted to detect a separation
between groups and to better identify the i.v. iron effect.10
Therefore, we believe that our results would have been similar
had we maintained the epoetin dose unchanged for 6 weeks
and randomized patients to 1 g of i.v. ferric gluconate vs. no
iron. The latter hypothetical study design was not possible
because many nephrologists felt it would be unethical to deny
patients the current recommendation by NKF K-DOQI of a
25% increase in epoetin dose.2,3,10
The results of ferritin and TSAT tests have long guided the
decision of whether to administer iron therapy to hemodia-
lysis patients. These tests are simply interpreted when
concordant. Unfortunately, the presence of inflammation
frequently compromises their ability to assess actual iron
status.11 High ferritin and low TSAT are commonly observed
in dialysis patients in clinical practice, and can usually be
explained by accompanying inflammation. Several studies
have attempted to investigate the ability of TSAT and serum
ferritin to differentiate between responders and non-respon-
ders to i.v. iron.5–9 Although these studies were smaller than
ours reported herein, contained very few or no patients with
baseline ferritin X500 ng/ml, and did not include a control
arm, they invariably observed that the TSAT and ferritin did
not predict response to i.v. iron.4 Our results in patients with
ferritin X500 ng/ml, TSATp25%, and apparently adequate
epoetin doses (mean baseline dose 450–500 IU/kg/week)
confirm those previous findings. Indeed, despite a belief
held by some that when ferritin levels exceed 500 ng/ml iron
stores are adequate and further i.v. iron administration is
likely to be ineffective,12,13 the primary finding of DRIVE is
that, in the setting of an increase in epoetin dose, giving 1 g of
ferric gluconate i.v. to this patient population is more
effective in improving hemoglobin levels than not giving
iron.10 Although DRIVE answers neither the question of iron
store adequacy in patients with ferritin of 500–1200 ng/ml
and TSATp25% nor the long-term patient outcomes of such
intervention, it demonstrates that these patients do benefit
from a course of i.v. iron insofar as resulting in an
improvement in iron parameters and in increasing hemo-
globin in a clinically significant manner. However, neither
TSAT nor ferritin provided sufficient discriminative value for
clinical use. The response was similar in patients with
baseline ferritin above or below 800 ng/ml.10 The response
was also similar when TSAT was above or below the median
of 19%.10
It has been suggested that sTfR is a sensitive indicator of
functional iron deficiency14 and a useful predictor of
hemoglobin response.15 However, it has been shown that
this marker offers no advantage over TSAT and ferritin in
identifying patients who would benefit from additional i.v.
iron treatments.16 Although sTfR levels are increased in the
setting of iron deficiency, they are also elevated as a result of
increased erythropoiesis induced by epoetin, thereby masking
the net effect of iron stores on this indicator.17 This may have
contributed to the failure of this marker to predict
hemoglobin response in this study. Given the high cost of
the sTfR assay (approximately US$125 per test) and its poor
discriminative properties, we do not recommend using it in
guiding i.v. iron therapy in this patient population.
The 2006 KDOQI anemia clinical practice recommenda-
tions1 advocate a target CHr level 429 pg/cell based on two
randomized controlled trials.18,19 Fishbane et al.,18 rando-
mized hemodialysis patients to receive i.v. iron based on CHr
or TSAT and ferritin criteria. In those receiving i.v. iron when
CHr dropped below 29 pg/cell, cost of anemia treatment and
cumulative i.v. iron administered was less than patients
randomized to receive i.v. iron based on TSAT o20% or
ferritin o100 ng/ml. The two groups had similar hematocrit
levels and epoetin doses at study end. Kaneko et al.19
randomized hemodialysis patients to receive i.v. iron when
their CHr dropped below 32.5 pg/cell or when TSAT fell
below 20%.There was no difference between the two groups
in hematocrit or epoetin dose change, but only the group
treated based on TSAT experienced a significant epoetin dose
decrease. Although not specifically pointed out by the 2006
KDOQI clinical practice recommendations, patients in both
studies (as well as studies investigating CHr’s ability to
identify responders to i.v. iron20,21) predominantly had
baseline ferritin levels o500 ng/ml. Consequently, results
from these two studies should be interpreted with caution
insofar as extrapolating them to patients with higher ferritin
levels. Although DRIVE did not target a specific CHr level by
design, it provides some insights into the relationship
between CHr levels and responsiveness to i.v. iron in patients
with ferritin of 500–1200 mg/ml, TSAT p25%, and adequate
epoetin dose. In such patients, CHr levels X31.2 pg/cell are
associated with greater response than lower levels. Owing to
fundamental design differences, our results cannot clearly be
compared with prior studies.
As shown in Table 1, 480% of patients with ferritin of
500–1200 ng/ml and TSAT p25% in DRIVE had a CHr
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429 pg/cell, that is, only o20% had a CHr o29pg/cell.
However, B47% of i.v. iron patients compared with only
about 29% of the no iron patients had a clinically significant
response.10 Had the KDOQI clinical practice recommenda-
tions’ CHr cutoff target value been correct for this patient
population, we would have expected only about 20% of
patients to respond. This shows that the 429 pg/cell CHr
cutoff value is exceedingly low and does not apply to this
population of hemodialysis patients. Interestingly, this
population is precisely the one that clinicians often have
trouble treating, causing them to resort to other iron
bioavailability indices, like CHr, to guide their iron manage-
ment decisions. Using the KDOQI recommended CHr cutoff
may lead clinicians to withhold i.v. iron from patients who
are very likely to benefit from it. Nevertheless, the sensitivity
and specificity of the X31.2 pg/cell CHr cutoff value were
only 63.9 and 75.0%, respectively. Because these discrimina-
tive properties are modest at best, and because the only
treatment known to raise CHr is to give i.v. iron, in light of
our findings, we do not recommend the use of CHr in
guiding i.v. iron administration decisions in this population.
It is unclear why higher rather than lower CHr levels were
associated with greater likelihood of response to i.v. iron. One
potential explanation is that patients with a low CHr have a
magnitude of iron deficiency such that 1 g of iron is
insufficient to generate a X2g/dl increase in hemoglobin.
Alternatively, the low CHr may reflect marked inability to
mobilize iron from reticuloendothelial stores, resulting in a
less efficient or delayed response to i.v. iron.
Our results suggest that inflammation, reflected by CRP
levels, reduces the likelihood and extent of responding to i.v.
iron, but does not exclude it. Compared with patients not
receiving iron, patients receiving i.v. ferric gluconate were
more than twice as likely to achieve a hemoglobin response
X2g/dl regardless of whether baseline CRP was above or
below 14.1 mg/l. These results support the administration of
a trial course of i.v. iron to patients with elevated CRP levels
and hemoglobin p11 g/dl despite adequate erythropoiesis-
stimulating agents therapy.
This report is the first to investigate the use of magnitude
of epoetin dose increases in predicting hemoglobin response
in the clinical context of iron therapy. Despite the fact that all
patients received a 25% increase in their baseline epoetin
doses, those in the no iron group who received X101 IU/kg/
week were 4–7 times more likely to mount a X2g/dl
hemoglobin response than those who received smaller
increases. In the i.v. iron group, likelihood of response was
unaffected by the absolute epoetin dose increase. This
suggests that patients with high ferritin and low TSAT on
lower epoetin doses will also have a high response rate to i.v.
iron therapy.
This analysis had potential limitations that merit discus-
sion. The DRIVE study comprised of individuals with a high
ferritin and low TSAT, receiving relatively high epoetin doses.
Hence, conclusions regarding the validity of the various
parameters of iron status and inflammation examined may
not be generalizable to all hemodialysis patients. However, it
is this patient group that is the most challenging to treat.1,2
The very high OR for the association between CHr level and
response to i.v. iron was associated with a wide confidence
interval. A larger sample size would be required to narrow
this confidence interval. The study did not measure the
percent of hypochromic red cells as delays in measurement
owing to shipping affect this test’s results. This test has been
reported to be an excellent predictor of iron responsive-
ness.6,22 Further studies to evaluate percent of hypochromic
red cells despite shipping delays may be warranted. We also
did not measure hepcidin as no validated serum hepcidin
assays were commercially available. Lastly, as we did not
perform bone marrow biopsies to ascertain true iron stores,
we were unable to generate any hypotheses regarding the
underlying causes that drive ferritin to higher levels.
However, others have reported that, in addition to predicting
iron status, higher ferritin levels may result from a
combination of inflammation and malnutrition in addition
to iron stores.23
The US Food and Drug Administration-approved labeling
for epoetin recommends that doses are decreased by 25%
when the rate of hemoglobin rise exceeds 1 g/dl in a 2-week
period.24 We found that this dosing change threshold was
achieved in approximately 42% of patients regardless of
treatment assignment. Therefore, we recommend that
patients of this sub-population who are given 25% epoetin
dose increase alone or in combination with 1 g i.v. iron
should be monitored closely so that appropriate dose
adjustments are made, especially in those with CRP levels
below 14.1 mg/l.
In conclusion, this study suggests efficacy for i.v. iron
therapy among anemic hemodialysis patients with ferritin
p1200 ng/ml and TSAT p25%. As continued i.v. iron use is
targeted to replace iron losses,2 our data do not support the
current National Kidney Foundation-Kidney Disease Out-
come Initiative suggestion of not treating patients with iron
when their serum ferritin levels exceed 500ng/ml. Indeed, we
suggest reconsideration of this recommendation. Our data
suggest that no iron response parameter we measured
warrants consideration in making an iron management
decision. Although our finding, that higher CHr rather than
lower CHr is associated with a greater likelihood of clinically
important hemoglobin response to i.v. iron, is hypothesis-
generating, our data suggest that CHr lacks adequate
sensitivity and specificity to be used in guiding iron
management decisions.
MATERIALS AND METHODS
The DRIVE study design and population were previously
described.10 Briefly, this study was an open-label, randomized,
controlled, multicenter trial conducted in 37 centers across the
United States. Eligible participants were maintenance hemodialysis
patientsX18 years with hemoglobinp11g/dl, TSATp25%, ferritin
of 500–1200 ng/ml, baseline epoetin doses X225 IU/kg/week or
X22 500 IU/week for X2 weeks, and who received p125 mg i.v.
Kidney International (2007) 71, 1163–1171 1169
AK Singh et al.: Predicting response to anemia treatment o r i g i n a l a r t i c l e
iron per week during the 4 weeks preceding screening/baseline.
Major exclusion criteria were significant blood loss within the prior
6 weeks, hematological disorders or malignancies, any active
infection requiring systemic antibiotic therapy, and hospitalization
within the 2 weeks before screening/baseline.
Patients were screened during week 0. Screening procedures
included obtaining blood samples for hematology and serum
chemistry assessments, including hemoglobin, TSAT, serum ferritin,
sTfR, CHr, CRP, and homocysteine. If screening blood tests revealed
TSAT p25%, ferritin 500–1200 ng/ml, and hemoglobin p11 g/dl,
the patients were considered eligible for the study and their
screening results were considered baseline values. Eligible patients
were centrally randomized 1:1 to either no iron or to 1 g of ferric
gluconate (Ferrlecits, Watson Laboratories, Inc., Morristown, NJ,
USA) administered in eight consecutive 125 mg doses beginning
with the first hemodialysis session of week 1 (i.v. iron group).
Baseline epoetin doses were raised by 25% in both groups starting
with the first hemodialysis session of week 1, and then maintained
for the entire study until the first hemodialysis session of week 6.
Hemoglobin and CHr were obtained weekly before the second
hemodialysis session throughout the 6-week study period.
All laboratory assessments were performed by a central
laboratory. Serum iron and unsaturated iron binding capacity
(UIBC), as well as the high sensitivity CRP, were obtained using the
Olympus AU5400 analyzer (Olympus Diagnostics, Melville, NY,
USA). Cobra Integra analyzer (Roche Diagnostics, Indianapolis, IN,
USA) was used for sTfR levels. Advia 120 analyzer (Bayer
Diagnostics) was used for CHr levels. Serum ferritin levels were
obtained using the Advia Centeur analyzer (Bayer Diagnostics).
DRIVE was conducted in compliance with the Declaration of
Helsinki, and approved by the human studies’ committee at each
center. All study participants provided informed consent before
undergoing any study procedures. This trial was registered with the
United States National Institutes of Health through the National
Library of Medicine at http://clinicaltrials.gov/.
Analysis objectives
There were two objectives to this analysis. First, to investigate how
baseline values of TSAT, serum ferritin, CHr, sTfR, and CRP and
epoetin dose increases given during the study (response markers)
impact change in hemoglobin levels from baseline to study end
(week 6 or last available hemoglobin for those not completing the
study) regardless of treatment assignment. Realizing that values of
these response markers may have a statistically, but not clinically
significant impact on hemoglobin changes, the other objective was
to explore how these markers influence the likelihood of achieving a
hemoglobin increase X2 g/dl to the assigned treatment. The
rationale for choosing this definition of response was discussed
previously.10
Statistical analyses
The primary predefined analysis was based on the ITT population,
which included participants who received at least one study
treatment and had at least one post-baseline hemoglobin value. A
predefined confirmatory analysis was performed based on the PP
population, which excluded participants who had any serious
protocol deviations, receivedo75% of the scheduled epoetin doses,
or o1000 mg of ferric gluconate (if randomized to i.v. iron).
The relationship between baseline response markers and
hemoglobin change at week 6, that is, the first objective was
analyzed using separate multiple linear regression models. Each
model included baseline hemoglobin, value of the response marker
being examined, and treatment arm (i.v. iron; yes/no). To achieve
the second objective, baseline values of each response marker were
grouped into two categories (omedian value vs Xmedian value).
The relationship between hemoglobin response and response
marker category was analyzed for each treatment arm separately
using logistic regression. All statistical tests were conducted at
a¼ 0.05 significance level. All statistical analyses were conducted
using SAS 8.2 (SAS Institute, Cary, NC, USA) or Stata 8.2
(StataCorp, College Station, TX, USA).
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